Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001651308-24-000129
Filing Date
2024-10-02
Accepted
2024-10-02 19:16:13
Documents
3
Period of Report
2024-09-27

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1727910966.html 3  
1 FORM 3 wk-form3_1727910966.xml 3 1670
2 EX-24 sharppoav2.htm EX-24 4821
3 GRAPHIC sharppoav2001.jpg GRAPHIC 291025
  Complete submission text file 0001651308-24-000129.txt   408954
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Sharp Shalini (Reporting) CIK: 0001377202 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37686 | Film No.: 241349433

Mailing Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108
Business Address C/O MOURANT GOVERNANCE SERVICES (CAYMAN) 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN E9 KY1-1108 13459494123
BeiGene, Ltd. (Issuer) CIK: 0001651308 (see all company filings)

EIN.: 981209416 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)